University of Cincinnati Physicians Company LLC

1. Janssen Research & Development, LLC $2,805,812 299 payments
2. Genentech, Inc. $964,244 67 payments
3. Pfizer Inc. $739,783 98 payments
4. Genzyme Corporation $591,671 61 payments
5. Teva Pharmaceuticals USA, Inc. $437,007 131 payments
6. Mirati Therapeutics, Inc. $417,717 2 payments
7. AstraZeneca Pharmaceuticals LP $378,219 31 payments
8. Aadi Bioscience, Inc. $369,599 13 payments
9. Merck Sharp & Dohme Corporation $323,837 2 payments
10. Biogen, Inc. $312,835 12 payments

1. An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression $612,439 47 payments
2. Evaluation of Fenebrutinib in RMS Patients II $424,932 26 payments
3. A Short term Exploratory Study to Evaluate Safety Tolerability and Pharmacokinetics of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents with Major Depressive Disorder Who Have an Inadequate Response to an SSRI and Psychotherapy $423,859 44 payments
4. A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1 $417,717 2 payments
5. A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Subjects Who Are Assessed to be at Imminent Risk for Suicide $382,324 36 payments
6. A Double blind Randomized Placebo Controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder Including Suicidal Ideation in Subjects Who Are Assessed to be at Imminent Risk for Suicide $370,764 31 payments
7. A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes $369,599 13 payments
8. A Phase 3 Randomized Doubleblind Study of Encorafenib and Binimetinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants With Braf V600ek Mutationpositive Metastatic Or Unresectable Locally Advanced Melanoma $344,053 35 payments
9. A Double blind Randomized Placebo Controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder Including Suicidal Ideation in Subjects Who Are Assessed to be at Imminent $328,219 32 payments
10. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa $279,992 2 payments

1. Patient care $5,235 6 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.